Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

Lyrica to be made class C drug in Northern Ireland

April 1, 2019 Sales and Marketing Lyrica, Northern Ireland, class c, illegal drugs, pain, pregabalin

Pregabalin – sold under the brand name Lyrica – will now be treated as a class C drug in Northern …
News
shutterstock_273326141

AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration

March 29, 2019 Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Daiichi Sankyo, pharma

AstraZeneca and Daiichi Sankyo have announced a new collaboration agreement to the tune of potentially $6.9 billion which will see …
News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 29, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

A Japanese journalist was ordered to pay ¥3.3 million to an anti-vaccine researcher, this week, after a court found her …
News
vertex-headquarters

Vertex destroyed nearly 8,000 packs of Orkambi in 2018

March 28, 2019 Medical Communications, Sales and Marketing Briatin, Orkambi, UK, Vertex, cystic fibrosis

Vertex destroyed nearly 8,000 packs of the $272,000 a year cystic fibrosis drug Orkambi in 2018, the company said in …
News

Working Life: Dr Paul-Peter Tak, ex-Senior Vice President, Development Lead and Chief Immunology Officer at GSK, Venture Partner at Flagship Pioneering

March 28, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Working Life, feature

Dr Paul-Peter Tak, ex-Senior Vice President, Development Lead and Chief Immunology Officer at GSK, Venture Partner at Flagship Pioneering.How did …
Feature

AstraZeneca’s Imfinzi to be made available via Cancer Drugs Fund in England

March 28, 2019 Sales and Marketing AstraZeneca, Cancer, Imfinzi, NHS, NICE, UK, lung cancer

AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will now be made available to English lung cancer patients on the NHS via the …
News

Gilead accused of ripping off US taxpayers

March 28, 2019 Medical Communications, Sales and Marketing CDC, Gilead, HIV, PrEP, Truvada, US government, patents

Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in …
News
abbvie_0

Japan awards AbbVie’s Skyrizi with first approval, in 4 psoriasis indications

March 27, 2019 Research and Development, Sales and Marketing AbbVie, Japan, Skyrizi, pharma, psoriasis

AbbVie has announced that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has been awarded approval in Japan from the nation’s Ministry …
News
novartis_side_building

Novartis’ new MS drug to cost $88,000 a year

March 27, 2019 Research and Development, Sales and Marketing FDA, MS, Novartis, Novartis pharmaceuticals, multiple sclerosis

Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will …
News
screen_shot_2019-02-19_at_14

Conducting internal investigations within a pharmaceutical business

March 25, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Reed Smith, feature, internal investigations, pharma

Though often necessary, internal investigations are seldom smooth or easy. Rosanne Kay, Partner at law firm Reed Smith, outlines a …
Feature
fda2outsideweb

Sanofi and Lexicon’s Zynquista denied type 1 diabetes approval by FDA complete response letter

March 25, 2019 Sales and Marketing Zynquista. FDA, diabetes, pharma

Sanofi and Lexicon’s Zynquista (sotagliflozin) has hit a hurdle on its way to US approval for the treatment of type …
News
takeda_usa_pharmaceuticals_u

NICE recommend Takeda’s lymphoma treatment Adcetris

March 25, 2019 Sales and Marketing Cancer, NICE, Takeda, UK, lymphoma, oncology, recommendation

Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma …
News
cannabis-2152604_960_720

Africa’s legal cannabis market could generate $7.1 billion each year by 2023

March 25, 2019 Sales and Marketing Africa, UN, cannabis, medicnial cannabis, prohibition partners

Africa’s legal cannabis market could generate more than $7.1 billion each year by 2023, according to a report from market …
News
astrazeneca_building_white

AZ’s diabetes drug Forxiga secures EU approval for adjunctive use in type 1 patients

March 25, 2019 Sales and Marketing AstraZeneca, Forxiga, diabetes, pharma

AstraZeneca has revealed that its sodium-glucose co-transporter 2 (SGLT2) inhibitor Forxiga (dapagliflozin) has secured approval from the European Commission for …
News
natural-homeopathic-remedy-alternative-homeopathy-1604071

Advertising Standards Authority tells therapists to stop marketing ‘autism cure’

March 25, 2019 Sales and Marketing ASA, CEASE therapy, advertising standards authority, anti-vaccines, autism, vaccines

The Advertising Standards Authority (ASA) has told British therapists to stop marketing a sham ‘cure’ for autism. The regulator told …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026